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worldwide (Madhi and Klugman, 2006; Troeger, et al., 2019). 
Bacterial-induced LRTI includes bronchitis and pneumonia 
and increases the risk of pulmonary complications (Kasper, 
et al., 2006). LRTIs are occurring in children and adult alike, 
peaking among patients in intensive care units (ICUs). The 
LRTI acquired in ICUs is best known as hospital-acquired 
LRTI (Yan, et al., 2018; Karlowsky, et al., 2020). LRTI 
adverse effects are not limited to population health, but they 
cause a tangible economic burden on the health-care systems 
(Ehlken, et al., 2005; Sinha, et al., 2013; Trucchi, et al., 2019).
The majority of bacterial-induced LRTIs are caused by 
Gram-negative bacteria (GNB), and lower case numbers 
caused by Gram-positive bacteria (GPB). Pseudomonas 
aeruginosa and Haemophilus influenzae (GNB) and 
Streptococcus pneumoniae (GPB) are among the most 
common bacterial isolates recovered from LTRIs (Kohlenberg, 
et al., 2008; Khan, et al., 2015). Viruses are also responsible 
for the development of LRTIs (Ren, et al., 2009; Huang, et al., 
2020) and antibiotics are often unnecessarily prescribed for 
treating these cases that may contribute to the emergence of 
antibiotic resistance (Pavia, 2011; Shiley, et al., 2015). 
Uncovering the etiologies of LRTI has a key role in 
making the right therapeutic decisions while dealing with 
this pathological condition (Brookes-Howell, et al., 2012; 
Langelier, et al., 2018). Unfortunately, in most cases, LRTI 
treatment is started before culture sensitivity tests are 
performed (Ali and Butt, 2017). Development of antibiotic 
resistance may also emerge once patients are given 
empiric therapy (Yin, et al., 2003; Fatima, et al., 2012; 
Claeys, et al., 2017). Hence, establishing standard guidelines 
to deal with LRTIs and their complications are vital to save 
lives, especially for those who already suffer from antibiotic-
resistant bacteria. In more server cases, LRTI patients may 
suffer from multidrug-resistant pathogens which may make 
their treatment even more challenging (Woodhead, et al., 
2011; Feldman and Richards, 2018).
There are guidelines in place and practiced in a few 
countries for LRTI management (Christiansen, 1996; Baturin, 
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I. Introduction
The lower respiratory tract infections (LRTIs) are common life-
threatening illnesses that frequently associated with mortalities 
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et al., 2015; Mahashur, 2018), but these guidelines are not 
practiced in Iraq. Building up awareness in public and among 
medical societies is crucial for establishing guidelines based 
on etiologies explicitly associated with each region. In regard 
to Erbil city, there are limited data available to represent 
etiologies of LRTI. Because of the above-stated reasons, and 
the probability of emergence of new antibiotic resistance 
cases among the locals in Erbil city (Al-Naqshbandi, et al., 
2019), this study was conducted as an attempt to uncover the 
current status of antibiotic sensitivity patterns of common 
bacterial isolates collected from LRTIs patients in Erbil city.
II. Materials and Methods
A. Specimen Collection and Transport
The LRT specimens (sputum and bronchial wash) were 
collected from patients attended Rizgary Teaching Hospital in 
Erbil city of Kurdistan Region, Iraq, for the period between 
January 2014 and December 2016. Sputum specimens were 
collected from patients after educating them to rinse their 
mouth with water and expectorate with the aid of a deep 
cough, in the first early morning and gathered directly 
into a labeled and sterile wide mouth screw cap container. 
Bronchial wash specimens were aspirated by a pulmonologist 
in the bronchoscopy unit and collected into a labeled and 
sterile screw cap container (Mahon, et al., 2014). Sputum and 
bronchial wash specimens were obtained separately and from 
different patients. After collection, 310 patients’ specimens 
were transported to laboratories of the Microbiology 
Department at Rizgary Hospital for analysis.
B. Bacterial Culture and Identification
Good microbiological laboratory practice was applied to 
deal with sputum or a pellet of centrifuged bronchial wash 
specimens. Later on, specimens were inoculated separately 
on blood, chocolate, and MacConkey agar. The inoculum was 
first smeared thoroughly over the surface of the pre-poured 
solidified medium. Then, the loop was resterilized and drawn-
out from the first site of inoculation into two or three parallel 
lines on fresh surfaces of the medium. A successive series of 
strokes were made with the loop that was sterilized between 
each sequence. At each step, the inoculum was derived from 
the most distal part of the immediately proceeded strokes. 
The plates were incubated overnight at 37°C. Number of 
colonies was counted to calculate bacterial numbers per ml 
of the specimens. The aerobically incubated bacterial growths 
were identified based on colony characteristics and outcome 
of Gram’s staining technique (Kumar, 2016). Identification 
of GPB and GNB genus and species tests were performed 
by following VITEK® 2 compact system (bioMérieux S.A., 
France) protocols using the following kits: VITEK®2 GN 
Reference 21341, VITEK®2 GP Reference 21342, and 
VITEK®2 AST-GN 82 Reference 413439.
C. Antibiotics
Antimicrobial sensitivity tests were investigated in this study 
through VITEK® 2 compact system (bioMérieux S.A., France) 
kits: VITEK®2 AST-P580 Reference 22233 and VITEK®2 AST-
ST01 Reference 410028. Following antibiotics were investigated 
in this study: AM – Ampicillin, AMC – Amoxicillin/clavulanic 
acid, AN – Amikacin, ATM – Aztreonam, CAZ – Ceftazidime, 
CIP – Ciprofloxacin, CM – Clindamycin, CRO – Ceftriaxone, 
CTX – Cefotaxime, CZ – Cefazolin, E – Erythromycin, ETP 
– Ertapenem, FA – Fusidic acid, FEP – Cefepime, FOS – 
Fosfomycin, FT – Nitrofurantoin, GM – Gentamicin, IPM 
– Imipenem, LEV – Levofloxacin, LNZ – Linezolid, MEM – 
Meropenem, MNO – Minocycline, MUP – Mupirocin, MXF 
– Moxifloxacin, OX1 – Oxacillin, P – Benzylpenicillin, PEF 
– Pefloxacin, PIP – Piperacillin, RA – Rifampicin, SAM – 
Ampicillin/sulbactam, SXT – Trimethoprim/sulfamethoxazole, 
TEC – Teicoplanin, TE – Tetracycline, TGC – Tigecycline, TIC 
– Ticarcillin, TM – Tobramycin, TZP – Piperacillin/tazobactam, 
and VA – Vancomycin.
D. Data Analysis
Bacterial isolates’ abundancy, their distribution, and drug 
sensitivity were presented in percentage (%). Isolates were 
considered resistant toward certain antibiotic(s) when the 
percentile of their resistance was equal or greater than 70%. 
For the collective antibiotic resistance in GPB and GNB, 
only the resisted drugs were presented with the value equal 
or greater than 90%. For these calculations, Microsoft Excel 
2010 was used. 
TABLE I
Distribution of bacterial growth of LRTI specimen’s culture





No growth of bacteria 7 (5.30) 26 (14.61)
Non-pathogenic bacteria 97 (73.49) 124 (69.66)
Pathogenic bacteria 28 (21.21) 28 (15.73)
Gram positive 7 (25) 0 (0)
Gram negative 21 (75) 28 (100)
TABLE II
Distribution of gram-positive and gram-negative bacteria isolated 
from LRTI specimen’s culture





Staphylococcus aureus 2 (28.57) 0 (0)
Streptococcus parasanguinis 3 (42.86) 0 (0)
Streptococcus pneumoniae 2 (28.57) 0 (0)





Acinetobacter baumannii 7 (33.33) 2 (7.14)
Enterobacter cloacae 1 (4.76) 0 (0)
Escherichia coli 4 (19.05) 4 (14.29)
Klebsiella oxytoca 1 (4.76) 0 (0)
Klebsiella pneumonia 3 (14.29) 5 (17.86)
Proteus mirabilis 1(4.76) 1 (3.57)
Pseudomonas aeruginosa 4 (19.05) 7 (25)
Serratia marcescens 0 (0) 9 (32.14)
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TABLE III
The responses of sputum gram-positive isolates to different antimicrobial agents
Agents Staphylococcus aureus (2) (%) Streptococcus parasanguinis (3) (%) Streptococcus pneumoniae (2) (%)
AM – Ampicillin R2 (100) R3 (100) R2 (100)
CM – Clindamycin R2 (100) R3 (100) S1 (50) R1 (50)
CRO – Ceftriaxone R2 (100) S2 (66.67) R1 (33.34) S2 (100)
CTX – Cefotaxime R2 (100) S1 (33.34) R2 (66.67) S2 (100)
E – Erythromycin R2 (100) R3 (100) R2 (100)
FA – Fusidic acid S2 (100) R3 (100) R2 (100)
FOS – Fosfomycin S2 (100) R3 (100) R2 (100)
FT – Nitrofurantoin S2 (100) R3 (100) R2 (100)
GM – Gentamicin S2 (100) R3 (100) R2 (100)
LEV – Levofloxacin R2 (100) R3 (100) R2 (100)
LNZ – Linezolid S2 (100) S3 (100) S2 (100)
MUP – Mupirocin S2 (100) R3 (100) R2 (100)
MXF – Moxifloxacin S2 (100) R3 (100) R2 (100)
OX1 – Oxacillin S2 (100) R3 (100) R2 (100)
P – Benzylpenicillin R2 (100) R3 (100) S2 (100)
RA – Rifampicin S2 (100) R3 (100) R2 (100)
SXT – Trimethoprim/sulfamethoxazole R2 (100) R3 (100) R2 (100)
TE – Tetracycline R2 (100) R3 (100) R2 (100)
TEC – Teicoplanin S2 (100) R3 (100) R2 (100)
TGC – Tigecycline S2 (100) R3 (100) R2 (100)
TM – Tobramycin S2 (100) R3 (100) R2 (100)
VA – Vancomycin S2 (100) S3 (100) S2 (100)
S: Sensitive; R: Resistant
TABLE IV


















AM – Ampicillin R7 (100) R1 (100) R4 (100) R1 (100) R3 (100) R1 (100) R4 (100)
AMC – Amoxicillin/
clavulanic acid
R7 (100) R1 (100) S1 (25) R3 (75) R1 (100) R3 (100) R1 (100) R4 (100)
AN – Amikacin R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S3 (100) S1 (100) R4 (100)
ATM – Aztreonam R7 (100) S1 (100) S3 (75) R1 (25) S1 (100) S3 (100) S1 (100) R4 (100)
CAZ – Ceftazidime R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S3 (100) S1 (100) S1 (25) R3 (75)
CIP – Ciprofloxacin R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S3 (100) R1 (100) R4 (100)
CRO – Ceftriaxone R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S2 (66.67) R1 (33.33) R1 (100) R4 (100)
CZ – Cefazolin R7 (100) R1 (100) S2 (50) R2 (50) S1 (100) S2 (66.67) R1 (33.33) R1 (100) R4 (100)
ETP – Ertapenem R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S2 (66.67) R1 (33.33) R1 (100) R4 (100)
FEP – Cefepime R7 (100) S1 (100) S3 (75) R1 (25) S1 (100) S3 (100) S1 (100) R4 (100)
FT – Nitrofurantoin R7 (100) R1 (100) S3 (75) R1 (25) R1 (100) R3 (100) R1 (100) S1 (25) R3 (75)
GM – Gentamicin R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S3 (100) S1 (100) S3 (75) R1 (25)
IPM – Imipenem R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S3 (100) R1 (100) R4 (100)
LEV – Levofloxacin R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S2 (66.67) R1 (33.33%) R1 (100) R4 (100)
MEM – Meropenem R7 (100) S1 (100) S3 (75) R1 (25) S1 (100) S3 (100) S1 (100) R4 (100)
MNO – Minocycline S1 (14.29) R6 (85.71) R1 (100) R4 (100) R1 (100) S1 (33.33) R2 (66.67%) R1 (100) R4 (100)
PEF – Pefloxacin R7 (100) R1 (100) R4 (100) R1 (100) S1 (33.33) R2 (66.67%) R1 (100) R4 (100)
PIP – Piperacillin R7 (100) R1 (100) R4 (100) R1 (100) R3 (100) S1 (100) R4 (100)
SAM – Ampicillin/
sulbactam
S2 (28.57) R5 (71.43) R1 (100) S1 (25) R3 (75) S1 (100) S2 (66.67) R1 (33.33) R1 (100) R4 (100)
SXT – Trimethoprim/
sulfamethoxazole
S2 (28.57) R5 (71.43) S1 (100) R4 (100) S1 (100) S3 (100) R1 (100) R4 (100)
TGC – Tigecycline S2 (28.57) R5 (71.43) S1 (100) S2 (50) R2 (50) R1 (100) S2 (66.67) R1 (33.33) R1 (100) R4 (100)
TIC – Ticarcillin R7 (100) S1 (100) R4 (100) R1 (100) R3 (100) S1 (100) R4 (100)
TM – Tobramycin R7 (100) R1 (100) S3 (75) R1 (25) S1 (100) S3 (100) S1 (100) S1 (25) R3 (75)
TZP – Piperacillin/
tazobactam
R7 (100) S1 (100) S2 (50) R2 (50) S1 (100) S3 (100) S1 (100) R4 (100)
S: Sensitive; R: Resistant
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TABLE V













AM – Ampicillin R2 (100) R4 (100) R5 (100) R1 (100) R7 (100) R9 (100)
AMC – Amoxicillin/
clavulanic acid
R2 (100) S1 (25) R3 (75) R5 (100) S1 (100) R7 (100) R9 (100)
AN – Amikacin R2 (100) S3 (75) R1 (25) S3 (60) R2 (40) R1 (100) S6 (85.71) R1 (14.29) S5 (55.56) R4 (44.44)
ATM – Aztreonam R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) R1 (100) R7 (100) S1 (11.11) R8 (88.89)
CAZ – Ceftazidime R2 (100) S3 (75) R1 (25) S3 (60) R2 (40) S1 (100) S7 (100) S4 (44.44) R5 (55.56)
CIP – Ciprofloxacin R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) S1 (100) S5 (71.43) R2 (28.57) S5 (55.56) R4 (44.44)
CRO – Ceftriaxone R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) S1 (100) R7 (100) S3 (33.33) R6 (66.67)
CZ – Cefazolin R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) S1 (100) R7 (100) R9 (100)
ETP – Ertapenem R2 (100) S3 (75) R1 (25) S3 (60) R2 (40) R1 (100) R7 (100) S7 (77.78) R2 (22.22)
FEP – Cefepime R2 (100) S3 (75) R1 (25) S3 (60) R2 (40) S1 (100) S6 (85.71) R1 (14.29) S8 (88.89) R1 (11.11)
FT – Nitrofurantoin R2 (100) S1 (25) R3 (75) R5 (100) S1 (100) S7 (100) S4 (44.44) R5 (55.56)
GM – Gentamicin R2 (100) S2 (50) R2 (50) S5 (100) S1 (100) S6 (85.71) R1 (14.29) S4 (44.44) R5 (55.56)
IPM – Imipenem R2 (100) S4 (100) S3 (60) R2 (40) R1 (100) S4 (57.14) R3 (42.86) S7 (77.78) R2 (22.22)
LEV – Levofloxacin R2 (100) S1 (25) R3 (75) S3 (60) R2 (40) S1 (100) S6 (85.71) R1 (14.29) S7 (77.78) R2 (22.22)
MEM – Meropenem R2 (100) S3 (75) R1 (25) S3 (60) R2 (40) R1 (100) S5 (71.43) R2 (28.57) S5 (55.56) R4 (44.44)
MNO – Minocycline R2 (100) S1 (25) R3 (75) R5 (100) R1 (100) S1 (14.29) R6 (85.71) S1 (11.11) R8 (88.89)
PEF – Pefloxacin R2 (100) S1 (25) R3 (75) R5 (100) R1 (100) S1 (14.29) R6 (85.71) S1 (11.11) R8 (88.89)
PIP – Piperacillin R2 (100) S1 (25) R3 (75) R5 (100) R1 (100) S1 (14.29) R6 (85.71) S1 (11.11) R8 (88.89)
SAM – Ampicillin/
sulbactam
R2 (100) S1 (25) R3 (75) S3 (60) R2 (40) S1 (100) R7 (100) R9 (100)
SXT – Trimethoprim/
sulfamethoxazole
R2 (100) S1 (25) R3 (75) S3 (60) R2 (40) R1 (100) S6 (85.71) R1 (14.29) S4 (44.44) R5 (55.56)
TGC – Tigecycline R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) R1 (100) R7 (100) S4 (44.44) R5 (55.56)
TIC – Ticarcillin R2 (100) S1 (25) R3 (75) R5 (100) R1 (100) R7 (100) S1 (11.11) R8 (88.89)
TM – Tobramycin R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) S1 (100) S6 (85.71) R1 (14.29) S4 (44.44) R5 (55.56)
TZP – Piperacillin/
tazobactam
R2 (100) S2 (50) R2 (50) S3 (60) R2 (40) S1 (100) S5 (71.43) R2 (28.57) S7 (77.78) R2 (22.22)
S: Sensitive; R: Resistant
III. Results
From different LRTIs patients, 132 sputum and 178 
bronchial wash specimens were collected. Out of all sputum 
specimens, 5.3% showed no bacterial growth, 73.49% showed 
non-pathogenic bacterial growth, and 21.21% generated 
pathogenic bacterial growth. Our data revealed that 14.61% 
of bronchial wash specimens showed no bacterial growth, 
69.66% produced non-pathogenic bacteria, and 15.73% 
generated pathogenic bacteria (Table I). About 25% of 
sputum pathogenic isolates were GPB (75% were GNB), and 
bronchial wash isolates were entirely GNB (Tables I and II).
Further analysis of sputum pathogenic isolates showed 
that Streptococcus parasanguinis was the most common 
GPB and Acinetobacter baumannii was the most common 
GNB. Bronchial wash specimens “entirely” generated GNB, 
and Serratia marcescens was the most detectable species 
(Table II). Antibiotic susceptibility tests for sputum Gram-
positive isolates showed that the most resistant bacteria were 
Streptococcus parasanguinis and the most sensitive one was 
Staphylococcus aureus (Table III). Antibiotic susceptibility 
test also showed that Acinetobacter baumannii was the 
most resistant sputum Gram-negative isolate, and Klebsiella 
pneumoniae was the most sensitive pathogenic bacteria 
(Table IV). Antibiotic susceptibility testes for bronchial wash 
Gram-negative isolates showed that Acinetobacter baumannii 
was the most resistant, and Klebsiella pneumoniae was the 
most sensitive bacteria (Table V).
Antibiotic susceptibility tests also showed that GPB, 
collectively, were highly resistant to the following 
antibiotics: Ampicillin, erythromycin, levofloxacin, 
trimethoprim/sulfamethoxazole, and tetracycline. Our data 
also showed that all GNB isolated from sputum specimens 
(except for Enterobacter cloacae) have different responses 
toward studied antibiotics in comparison with the same 
bacteria that were isolated from bronchial wash specimens 
(Tables VI and VII). 
Staphylococcus aureus recovered from sputum specimens 
were sensitive to thirteen different types of antibiotics 
(Table III). Klebsiella pneumoniae recovered from sputum 
specimens was sensitive toward 19 different types of 
antibiotics (Table IV). K. pneumoniae recovered from 
bronchial wash specimens was sensitive toward 17 different 
types of antibiotics (Table V).
IV. Discussion
In this study, 310 specimens were collected from patients 
hospitalized for LRIs treatment and then investigated for 
bacterial distribution patterns and antibiotic sensitivity. Our data 
showed no bacterial growths in 5.3% of sputum and 14.61% of 
bronchial wash specimens (Table I). The undetectable bacterial 
growth might not reflect the absence of LRIs, as some LRIs 
cases are due to fungal or viral infections (Troeger, et al., 
2019; Barac, et al., 2018). However, this suggestion was not 
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conformed since the focus of this study was only on bacteria. 
On the other hand, there is a possibility that some of the non-
bacterial growths are due to anaerobic bacteria (Brook, 1997; 
Kedzia, et al., 2003), since we did not culture our specimens 
in anaerobic conditions we cannot confirm that. 
Our data also showed that more than 73% of sputum 
and about 70% of bronchial wash specimens generated 
non-pathogenic bacterial growth, and this may indicate 
the presence of normal flora in the collected specimens 
(Budayanti, et al., 2019). 
From 21.21% sputum specimens pathogenic bacteria 
were recovered (25% GPB and 75% GNB). Streptococcus 
parasanguinis (42.86%) was the most abundant one among 
GPB, and Acinetobacter baumannii (33.33%) was the 
most abundant one among GNB. Out of all bronchial wash 
specimens, 15.73% of them generated pathogenic bacteria 
(100% GNB), and Serratia marcescens (32.14%) was the 
TABLE VI
Pattern of antimicrobial resistance among detected bacteria
Isolate type No. of R.A. Resisted antibiotics
Sputum Gram-positive isolates
Streptococcus parasanguinis 18 Ampicillin, Clindamycin, Erythromycin, Fusidic acid, Fosfomycin, Nitrofurantoin, Gentamicin, Levofloxacin, 
Mupirocin, Moxifloxacin, Oxacillin, Benzylpenicillin, Rifampicin, Trimethoprim/Sulfamethoxazole, Tetracycline, 
Teicoplanin, Tigecycline, Tobramycin.
Streptococcus pneumoniae 16 Ampicillin, Erythromycin, Fusidic acid, Fosfomycin, Nitrofurantoin, Gentamicin, Levofloxacin, Mupirocin, 
Moxifloxacin, Oxacillin, Rifampicin, Trimethoprim/Sulfamethoxazole, Tetracycline, Teicoplanin, Tigecycline, 
Tobramycin.
Staphylococcus aureus 9 Ampicillin, Clindamycin, Ceftriaxone, Cefotaxime, Erythromycin, Levofloxacin, Benzylpenicillin, Trimethoprim/
Sulfamethoxazole, Tetracycline.
Sputum Gram-negative isolates
Acinetobacter baumannii 24 Ampicillin, Amoxicillin/clavulanic acid, Amikacin, Aztreonam, Ceftazidime, Ciprofloxacin, Ceftriaxone, 
Cefazolin, Ertapenem, Cefepime, Nitrofurantoin, Gentamicin, Imipenem, Levofloxacin, Meropenem, Minocycline, 
Pefloxacin, Piperacillin, Ampicillin/sulbactam, Trimethoprim/sulfamethoxazole, Tigecycline, Ticarcillin, 
Tobramycin, Piperacillin/tazobactam. 
Pseudomonas aeruginosa 23 Ampicillin, Amoxicillin/clavulanic acid, Amikacin, Aztreonam, Ceftazidime, Ciprofloxacin, Ceftriaxone, 
Cefazolin, Ertapenem, Cefepime, Nitrofurantoin, Imipenem, Levofloxacin, Meropenem, Minocycline, Pefloxacin, 
Piperacillin, Ampicillin/sulbactam, Trimethoprim/sulfamethoxazole, Tigecycline, Ticarcillin, Tobramycin, 
Piperacillin/tazobactam.
Proteus mirabilis 14 Ampicillin, Amoxicillin/clavulanic acid, Ciprofloxacin, Ceftriaxone, Cefazolin, Ertapenem, Nitrofurantoin, 
Imipenem, Levofloxacin, Minocycline, Pefloxacin, Ampicillin/sulbactam, Trimethoprim/sulfamethoxazole, 
Tigecycline.
Enterobacter cloacae 9 Ampicillin, Amoxicillin/clavulanic acid, Cefazolin, Nitrofurantoin, Minocycline, Pefloxacin, Piperacillin, 
Ampicillin/sulbactam, Tobramycin.
Escherichia coli 8 Ampicillin, Amoxicillin/clavulanic acid, Amikacin, Minocycline, Pefloxacin, Piperacillin, Ampicillin/sulbactam, 
Trimethoprim/sulfamethoxazole.
Klebsiella oxytoca 8 Ampicillin, Amoxicillin/clavulanic acid, Nitrofurantoin, Minocycline, Pefloxacin, Piperacillin, Tigecycline, 
Ticarcillin. 
Klebsiella pneumoniae 5 Ampicillin, Amoxicillin/clavulanic acid, Nitrofurantoin, Piperacillin, Ticarcillin.
Bronchial wash Gram-negative isolates
Acinetobacter baumannii 24 Ampicillin, Amoxicillin/clavulanic acid, Amikacin, Aztreonam, Ceftazidime, Ciprofloxacin, Ceftriaxone, 
Cefazolin, Ertapenem, Cefepime, Nitrofurantoin, Gentamicin, Imipenem, Levofloxacin, Meropenem, Minocycline, 
Pefloxacin, Piperacillin, Ampicillin/sulbactam, Trimethoprim/sulfamethoxazole, Tigecycline, Ticarcillin, 
Tobramycin, Piperacillin/tazobactam.
Pseudomonas aeruginosa 12 Ampicillin, Amoxicillin/clavulanic acid, Aztreonam, Ceftriaxone, Cefazolin, Ertapenem, Minocycline, Pefloxacin, 
Piperacillin, Ampicillin/sulbactam, Tigecycline, Ticarcillin.
Proteus mirabilis 12 Ampicillin, Amikacin, Aztreonam, Ertapenem, Imipenem, Meropenem, Minocycline, Pefloxacin, Piperacillin, 
Trimethoprim/sulfamethoxazole, Tigecycline, Ticarcillin.
Escherichia coli 10 Ampicillin, Amoxicillin/clavulanic acid, Nitrofurantoin, Levofloxacin, Minocycline, Pefloxacin, Piperacillin, 
Ampicillin/sulbactam, Trimethoprim/sulfamethoxazole, Ticarcillin.
Serratia marcescens 9 Ampicillin, Amoxicillin/clavulanic acid, Aztreonam, Cefazolin, Minocycline, Pefloxacin, Piperacillin, Ampicillin/
sulbactam, Ticarcillin.
Klebsiella pneumoniae 7 Ampicillin, Amoxicillin/clavulanic acid, Nitrofurantoin, Minocycline, Pefloxacin, Piperacillin, Ticarcillin.
R.A.: Resisted antibiotic
most abundant species (Table II). In regard to bacterial 
genus and species, different results were reported in other 
studies carried out in other countries in the past few years. 
Khan, et al. (2015) reported that Pseudomonas aeruginosa 
and Haemophilus influenzae (GNB) and Streptococcus 
pneumoniae (GPB) were the most detectable bacteria in LTRIs 
patient. Furthermore, Tchatchouang, et al. (2019) reported in 
their study that Streptococcus pneumoniae and Haemophilus 
influenzae were the most abundant bacteria in LRTI and 
followed by Klebsiella pneumoniae and Staphylococcus 
aureus (Khan, et al., 2015; Tchatchouang, et al., 2019). Since 
GNB represent more than 87% of all pathogenic bacteria 
recovered from our specimens, they were the most LRTI 
associated pathogens, and this came in agreement with other 
studies (Kohlenberg, et al., 2008; Bali, et al., 2016).
For antibiotic sensitivity tests, our data showing that among 
GPB recovered from sputum specimens, Streptococcus 
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are required to assess bacterial profile and antibiotic sensitivity 
patterns in different time points to uncover the pace of 
antibiotic resistance among LRTI patients in Erbil city.
V. Conclusion
From this study, we conclude that some of LRTIs are not 
due to bacterial infections. LRTIs are mainly associated with 
GNB. This study considers Streptococcus parasanguinis and 
Acinetobacter baumannii to be multidrug-resistant pathogens 
because these two specimens collected bacteria resisted 
most of the tested antibiotics. The antibiotic drug ampicillin 
was found to be ineffective in the eradication of all types 
of recovered pathogenic bacteria. Consequently, there is a 
pronounced chance of antibiotic resistance problem among 
LRTI patients. As this study finding can establish a startup 
for LRTI, further studies are required for better detection of 
antibiotic resistance pattern development among the locals in 
Erbil city.
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